The review found no eligible studies for this question.
Summary of findings: anti‐VEGF treatment probably leads to higher mean change in vision‐related quality of life compared with control (moderate certainty).
Summary of findings: anti‐VEGF treatment showed no clear difference in serious systemic adverse events at 1 year compared with control (moderate certainty).
Summary of findings: anti‐VEGF treatment showed no clear difference in serious ocular adverse events at 1 year compared with control (moderate certainty).
Summary of findings: quinolone prophylaxis probably leads to higher all cause‐mortality compared with TMP‐SMZ prophylaxis (moderate certainty).
Summary of findings: quinolone prophylaxis probably leads to lower febrile patients and episodes compared with TMP‐SMZ prophylaxis (moderate certainty).
Summary of findings: Specialist inpatient care for weight restoration showed no clear difference in weight or BMI (at end of 12 months from the start of treatment) compared with active outpatient or combination brief hospital/outpatient care (low certainty).
It is very uncertain whether summary of findings: Specialist inpatient care for weight restoration changes acceptability: number of participants who completed treatment (at… compared with active outpatient or combination brief hospital/outpatient care (very low certainty).
Summary of findings table ‐ Fitusiran prophylaxis probably leads to higher proportion with zero bleeds compared with on‐demand therapy (moderate certainty).
Summary of findings table ‐ Fitusiran prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).
Summary of findings table ‐ Fitusiran prophylaxis showed no clear difference in serious adverse events compared with on‐demand therapy (moderate certainty).
Summary of findings table ‐ Fitusiran prophylaxis probably leads to higher proportion with zero bleeds compared with on‐demand therapy (moderate certainty).
Summary of findings table ‐ Fitusiran prophylaxis probably leads to higher all adverse events compared with on‐demand therapy (moderate certainty).